Revenue
No reported data
AN2 Therapeutics, Inc. (ANTX)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Research & development | $24.8M | $40.5M | $54.9M | $28.5M | $16.2M |
| Operating expenses | $38.1M | $56.8M | $69.6M | $42.3M | $21.6M |
| Operating income | −$38.1M | −$56.8M | −$69.6M | −$42.3M | −$21.6M |
| Net income | −$35.2M | −$51.3M | −$64.7M | −$41.0M | −$21.5M |
| Basic EPSper diluted share | -$1.16 | -$1.72 | -$2.74 | -$2.79 | -$10.64 |
| Diluted EPSper diluted share | -$1.16 | -$1.72 | -$2.74 | -$2.79 | -$10.64 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 29, 2026Form 4 | Williams Sarah JoannePrincipal Accounting Officer | SellCommon Stock | 265 | $4.43 | $1.2K | 66.6K |
| Mar 3, 2026Form 4 | Williams Sarah JoannePrincipal Accounting Officer | SellCommon Stock | 327 | $1.06 | $346.62 | 66.8K |
| Jan 6, 2026Form 4 | Day LucyChief Financial Officer | SellCommon Stock | 5.5K | $1.01 | $5.6K | 75.4K |
| Jan 6, 2026Form 4 | Prior Stephen DavidChief Strategy Officer | SellCommon Stock | 2.9K | $1.01 | $2.9K | 59.1K |
| Jan 6, 2026Form 4 | Chanda SanjayChief Development Officer | SellCommon Stock | 6.0K | $1.01 | $6.0K | 75.8K |